



23<sup>rd</sup> October 2019

To,

**BSE LIMITED**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sir,

**Sub: Board Meeting Intimation**

Pursuant to clause 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR) we enclose advertisements given in Economic Times, Business Standard and Maharashtra Times relating publication of financial results for quarter and half year ended 30<sup>th</sup> September 2019.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President – Administration, Real Estate  
& Company Secretary

Encl: Public Notice

न सकाळी सातपासून दुपारी चार वाजेपर्यंत  
रू मतदान प्रक्रिया सुरळीत सुरू होती.  
ते. त्यानंतर दीपक रघुनाथ पवार यांनी  
वा आक्षेप घेतला. मतदान केंद्राध्यक्षांनी  
चाचणी मतदानासाठी अर्ज करण्यास  
सांगितले होते. मात्र, पवार यांनी  
री तसा अर्ज करण्यास नकार दिल्याने  
री मतदान केंद्रावर पुढील मतदान प्रक्रिया  
ण, सुरळीत पार पडली. वृत्तवाहिन्यांवर  
त जी दाखविण्यात येणाऱ्या बातमीत कोणतेही  
री तथ्य नाही, अशी कोणतीही घटना  
चे घडलेली नाही.

BASIC / Limited (₹10/- per share) (not annualised)  
(Face value per Share of INR 10/- each)

0.62

3.65

2.50

**Notes:**

- 1 The aforesaid unaudited Consolidated Financial Results and unaudited Standalone Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on October 22, 2019.
- 2 The above is an extract of the detailed format of the Unaudited Consolidated Financial Results and Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2019 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the quarter and half year ended September 30, 2019 is available on the website of the Stock Exchanges www.nseindia.com and www.bseindia.com and on the Company's website www.shardacropchem.com

Place: Mumbai

Date: October 22, 2019

For Sharda Cropchem Limited  
R. V. Bubna  
Chairman & Managing Director  
(DIN: 00136568)



## ग्लॅक्सोस्मिथक्लाइन फार्मास्युटिकल्स लिमिटेड

नोंदणीकृत कार्यालय : डॉ. अंती वेदंठ रोड, मुंबई ४०००३० • वेबसाईट : www.gsk-india.com

ई मेल : askus@gsk.com • कॉर्पोरेट आयडेंटिटी क्रमांक : L24239MH1924PLC001151

### ३० सप्टेंबर, २०१९ ला संपलेल्या तिमाही आणि अर्ध्या वर्षाकरिता एकल (Standalone) आणि एकत्रित अलेखापरिक्षित वित्तीय निष्कर्षांचे विवरण

(₹ लाखांत)

तपशिल	एकल (Standalone)				एकत्रित			
	अलेखापरिक्षित	अलेखापरिक्षित	अलेखापरिक्षित	लेखापरिक्षित	अलेखापरिक्षित	अलेखापरिक्षित	अलेखापरिक्षित	लेखापरिक्षित
	३०.०९.१९ ला संपलेले तीन महिने	३०.०९.१९ ला संपलेले सहा महिने	३०.०९.१८ ला संपलेले संबंधित तीन महिने	३१.०३.२०१९ ला संपलेले वर्ष	३०.०९.१९ ला संपलेले तीन महिने	३०.०९.१९ ला संपलेले सहा महिने	३०.०९.१८ ला संपलेले संबंधित तीन महिने	३१.०३.२०१९ ला संपलेले वर्ष
प्रचलनातून एकूण उत्पन्न	८८२१०	१६७०१२	८१६३१	३१२८५३	८८२०२	१६६९९९	८१६३१	३१२८१२
अपवादात्मक बाबीपूर्वी नफा	१८६२३	३६२२६	१६८२५	६५८८२	१८६२७	३६२३८	१६८३१	६५३९७
अपवादात्मक बाबी	४०११४	४०११४	(११७९)	४९८	४०११४	४०११४	(११७९)	२८६९
करापूर्वी नफा	५८७३७	७६३४०	१५६४६	६६३७१	५८७४१	७६३५२	१५६५२	६८२६६
कालावधी/वर्षाकरिता निव्वळ नफा	५०२७९	६१६२५	१००७७	४२५३६	५०२७५	६१६२९	१००८३	४४५३९
कालावधीकरिता एकूण व्यापक उत्पन्न	५००७७	६१४२३	१००७७	४१९८७	५००७३	६१४२७	१००८३	४३९९०
भरणा केलेले समभाग भांडवल (दर्शनी मुल्य प्रती भाग ₹ १०)	१६९४१	१६९४१	१६९४१	१६९४१	१६९४१	१६९४१	१६९४१	१६९४१
इतर इक्विटी	-	-	-	१९७३०१	-	-	-	१९७३०२
प्रति भाग मिळकत (ईपीएस) (₹ १० प्रत्येकी)								
अपवादात्मक बाबीनंतर बेसिक आणि डायल्युटेड ईपीएस (₹)	२९.६८	३६.३८	५.९५	२५.१९	२९.६८	३६.३८	५.९५	२६.२९
अपवादात्मक बाबीपूर्वी बेसिक आणि डायल्युटेड ईपीएस (₹)	८.३०	१५.००	६.४०	२५.०७	८.३०	१५.००	६.४०	२४.८५
	वार्षिक नाही				वार्षिक नाही			

**सूचना :**

१. ३० सप्टेंबर, २०१९ ला संपलेल्या तिमाही आणि सहा महिन्यांकरिता वित्तीय निष्कर्षांच्या तपशिलवार स्वरूपाचे उपरोक्त सार सेबी (लिस्टिंग ऑब्जेक्शनस अंण्ड डिस्कलोजर रिक्वायरमेंट्स) रेग्युलेशन्स, २०१५ च्या रेग्युलेशन ३३ अंतर्गत स्टॉक एक्सचेंजेस सोबत फाईल केले. सदर वित्तीय निष्कर्षांचे संपूर्ण स्वरूप कंपनीची वेबसाईट [www.gsk-india.com](http://www.gsk-india.com) येथे आणि स्टॉक एक्सचेंजेसची वेबसाईट [www.nseindia.com](http://www.nseindia.com) आणि [www.bseindia.com](http://www.bseindia.com) येथे उपलब्ध आहेत.
२. उपरोक्त निष्कर्षांचा लेखा समितीने आढावा घेतला आणि २२ ऑक्टोबर, २०१९ रोजी झालेल्या त्यांच्या संबंधित बैठकीत संचालक मंडळद्वारे त्यानंतर मान्यता देण्यात आली.

ठिकाण: मुंबई  
२२ ऑक्टो, २०१९

मंडळाच्या आदेशाद्वारे  
अण्णास्वामी वेधीशा  
व्यवस्थापकीय संचालक  
DIN: 144303



hrs at the venue mentioned at para 2 above.

8. Date of opening of Commercial Bids will be intimated to technical qualified firms only after evaluation of technical quotes.
9. Bidders are requested to offer their best discounted prices.
10. Purchaser reserves the right to reject any Tender Documents.
11. Conditional Tenders will not be accepted.

Sd/  
(Pardeep Kumar)  
Director of Naval Armament  
for and on behalf of the President of India

davp 10702/11/0178/1920

Katra Railway Colony

Hotel "Lemon Tree", Katra, J&K Respectively

Last Date of Submission of E-bid Online: 10<sup>th</sup> Dec. 2019 upto 15:00 Hrs.

Land Parcel	Plot Area (SQM)	FSI Offered	Permissible FSI	Bid Security	Reserve Price
A	7521.46	2.10	2.60	Rs. 35.00 Lakhs	Rs. 14.18 Crore
B	7831.23	2.10	2.60	Rs. 35.00 Lakhs	Rs. 14.97 Crore

For further details of the project, please visit our website [www.rlda.indianrailways.gov.in](http://www.rlda.indianrailways.gov.in) or on e-procurement Portal [www.tenderwizard.com/RLDA](http://www.tenderwizard.com/RLDA) under the heading 'e-tender'

For any clarifications, may please contact:-

DGM/RLDA, 97176 31068 dgmrs@rlda.railnet.gov.in	GM/RLDA, 97176 31055 gmri@rlda.railnet.gov.in	Consultant/RLDA, 93182 08062 alok.sinha@n.knightfrank.com
--	--	--

Note:- Any Corrigendum or Addendum shall be published only on RLDA's Website.

DGM/Tender, (M) 7703918078



## GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai 400030 • Website: [www.gsk-india.com](http://www.gsk-india.com)

Email: [askus@gsk.com](mailto:askus@gsk.com) • Corporate Identity Number: L24239MH1924PLC001151

### STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER, 2019

(₹ Lakhs)

Particulars	Standalone				Consolidated			
	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
	Three months ended 30.09.19	Six months ended 30.09.19	Corresponding Three months ended 30.09.18	Year Ended 31.03.2019	Three months ended 30.09.19	Six months ended 30.09.19	Corresponding Three months ended 30.09.18	Year Ended 31.03.2019
Revenue from Operations	88210	167012	81631	312853	88202	166999	81631	312812
Profit before Exceptional Items	18623	36226	16825	65882	18627	36238	16831	65397
Exceptional Items	40114	40114	(1179)	489	40114	40114	(1179)	2869
Profit before tax	58737	76340	15646	66371	58741	76352	15652	68266
Net Profit for the period / year	50279	61625	10077	42536	50275	61629	10083	44539
Total comprehensive Income for the period	50077	61423	10077	41987	50073	61427	10083	43990
Paid-up Equity Share Capital (Face value per share ₹ 10)	16941	16941	16941	16941	16941	16941	16941	16941
Other Equity	-	-	-	197301	-	-	-	197042
Earnings Per Share (EPS) (of ₹ 10 each)								
Basic and diluted EPS after Exceptional Items (₹)	29.68	36.38	5.95	25.11	29.68	36.38	5.95	26.29
Basic and diluted EPS before Exceptional Items (₹)	8.30	15.00	6.40	25.07	8.30	15.00	6.40	24.85
	Not Annualised				Not Annualised			

**Notes:**

1. The above is an extract of the detailed format of the Unaudited Financial Results for the quarter and six months ended 30<sup>th</sup> September, 2019 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at [www.gsk-india.com](http://www.gsk-india.com) and on the website of Stock Exchanges at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)
2. The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 22<sup>nd</sup> October, 2019.

By Order of the Board  
Annaswamy Vaidheesh  
Managing Director  
DIN: 14443037

Place: Mumbai  
22<sup>nd</sup> Oct, 2019

Economic Times (Mumbai) 23-10-2019 P-15

111





**GlaxoSmithKline Pharmaceuticals Limited**

Registered Office: Dr. Annie Besant Road, Mumbai 400030 • Website: www.gsk-india.com  
 Email: askus@gsk.com • Corporate Identity Number: L24239MH 11924PLC001151

**STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER, 2019**

(₹ Lakhs)

Particulars	Standalone				Consolidated			
	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
	Three months ended 30.09.19	Six months ended 30.09.19	Corresponding Three months ended 30.09.18	Year Ended 31.03.2019	Three months ended 30.09.19	Six months ended 30.09.19	Corresponding Three months ended 30.09.18	Year Ended 31.03.2019
Revenue from Operations	88210	167012	81631	312853	88202	166999	81631	312812
Profit before Exceptional Items	18623	36226	16825	65882	18627	36238	16831	65397
Exceptional Items	40114	40114	(1179)	489	40114	40114	(1179)	2869
Profit before tax	58737	76340	15646	66371	58741	76352	15652	68266
Net Profit for the period / year	50279	61625	10077	42536	50275	61629	10083	44539
Total comprehensive income for the period	50077	61423	10077	41987	50073	61427	10083	43990
Paid-up Equity Share Capital (Face value per share ₹ 10)	16941	16941	16941	16941	16941	16941	16941	16941
Other Equity	-	-	-	197301	-	-	-	197042
Earnings Per Share (EPS) (of ₹ 10 each)								
Basic and diluted EPS after Exceptional Items (₹)	29.68	36.38	5.95	25.11	29.68	36.38	5.95	26.29
Basic and diluted EPS before Exceptional Items (₹)	8.30	15.00	6.40	25.07	8.30	15.00	6.40	24.85
	Not Annualised				Not Annualised			

- Notes:**
- The above is an extract of the detailed format of the Unaudited Financial Results for the quarter and six months ended 30<sup>th</sup> September, 2019 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at [www.gsk-india.com](http://www.gsk-india.com) and on the website of Stock Exchanges at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)
  - The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 22<sup>nd</sup> October, 2019.

By Order of the Board  
**Annaswamy Vaidheesh**  
 Managing Director  
 DIN: 1444303

Place: Mumbai  
 22<sup>nd</sup> Oct, 2019

**PPAP AUTOMOTIVE LIMITED**  
 CIN: L74899DL1995PLC073281  
 Registered Office: 54, Okhla Industrial Estate, Phase-III, New Delhi-110020  
 Corporate Office: B-206A, Sector-81, Phase-II, Noida-201305 (U.P.)  
 Tel: +91-120-2462552 / 53; Fax: +91-120-2461371  
 Website: [www.ppapco.in](http://www.ppapco.in); E-mail ID: [investorservice@ppapco.com](mailto:investorservice@ppapco.com)

(₹ in lakhs)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019				
S.No.	PARTICULARS	QUARTER ENDED	HALF YEAR ENDED	QUARTER ENDED
		30.09.2019	30.09.2019	30.09.2018
Unaudited				
1	Total income from operations (net)	8,538.66	17,765.04	11,887.94
2	Net profit for the period (before tax, exceptional and / or extraordinary items)	391.58	1,227.85	1,656.89
3	Net profit for the period before tax (after exceptional and / or extraordinary items)	391.58	1,227.85	1,656.89
4	Net profit for the period after tax (after exceptional and / or extraordinary items)	432.28	1,008.22	1,156.81